Ventrus Biosciences Inc.
Formerly South Island Biosciences, Inc.
Ventrus Biosciences Inc. is listed today as Assembly Biosciences, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2010 | $3 M | No. 1 | $2 to $10 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Ventrus Biosciences Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2010).
SEC Form D · Apr 2010
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2010
That is all the official record says: Ventrus Biosciences Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Ventrus Biosciences Inc. are on record.
Investors#
No investor of Ventrus Biosciences Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 44 investors.
Largest shareholders today
Institutions holding Assembly Biosciences, Inc. shares, as of Sep 30, 2026.
- Gilead Sciences, Inc.$117 M24.31%
- Farallon Capital Management, L.L.C.$38 M7.84%
- Paradigm Biocapital Advisors LP$36 M7.59%
- BlackRock, Inc.$35 M7.27%
- Ra Capital Management, L.P.$24 M4.98%
- Parkman Healthcare Partners LLC$19 M3.89%
- Vanguard Capital Management LLC$14 M2.94%
- State Street Corp$13 M2.73%
- Millennium Management LLC$12 M2.39%
- Commodore Capital LP$11 M2.26%
- Seven Fleet Capital Management LP$10 M2.04%
- Citadel Advisors LLC$9 M1.85%
- Point72 Asset Management, L.P.$9 M1.77%
- Geode Capital Management, LLC$8 M1.76%
- Ameriprise Financial Inc$7 M1.41%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Thom Rowland | Acting President | Apr 2010 |
| Joseph Felder | Director | Apr 2010 |
| Thom Rowland | Acting President | Apr 2010 |
Went public since 2010. Its SEC number is that of a company listed on a stock exchange.